ASCO 2022: New Treatments and Novel Therapies in Advanced Bladder Cancer

Cheryl Lee, MD


June 20, 2022

Cheryl Lee, MD, reflects on her experience at ASCO 2022, a meeting at which she appreciated "the energy of 30,000 oncologists" and showcased new treatments and new therapies in the space of bladder cancer. In the non–muscle-invasive bladder cancer space, Dr Lee reviews the impressive outcomes from the QUILT-3.032 study which assessed the IL-15 superagonist N-803 in the treatment of BCG-unresponsive patients.

Next, Dr Lee reflects on the SWOG S1314 study, which looked at circulating-free DNA as a predictive biomarker of patient response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC). Finally, Dr Lee looks at the mixed results of two studies, the COSMIC-021 study and LEAP-011 trial, which assessed novel agents, yielding some potential benefits for more challenging MIBC patient populations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.